drugset / Trial / NCT00496587
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma. The safety of this drug combination will also be tested.
Timeline
- Start
- 2007-07
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Subject | Gemcitabine | Small molecule | 900 mg/m2 | Intravenous |